Get the Stockscreener App
13.37
1.62%
-0.22
Nextcure Inc stock is traded at $13.37, with a volume of 48,523.
It is down -1.62% in the last 24 hours and up +20.02% over the past month.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
See More
Previous Close:
$13.59
Open:
$13.57
24h Volume:
48,523
Relative Volume:
0.83
Market Cap:
$46.87M
Revenue:
-
Net Income/Loss:
$-58.52M
P/E Ratio:
-6.3971
EPS:
-2.09
Net Cash Flow:
$-45.03M
1W Performance:
+0.68%
1M Performance:
+20.02%
6M Performance:
+2,871%
1Y Performance:
+1,471%
1-Day Range:
$12.91
$13.98
1-Week Range:
$12.91
$14.09
52-Week Range:
$0.224
$15.74
Nextcure Inc Stock (NXTC) Company Profile
Name
Nextcure Inc
Sector
Industry
Phone
240-399-4900
Address
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
13.37 | 47.64M | 0 | -58.52M | -45.03M | -2.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Nov-04-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| Mar-05-21 | Upgrade | Truist | Hold → Buy |
| Jan-15-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-16-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-13-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-13-20 | Downgrade | SunTrust | Buy → Hold |
| Jun-01-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-01-20 | Downgrade | The Benchmark Company | Buy → Hold |
| May-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Mar-24-20 | Initiated | The Benchmark Company | Buy |
| Mar-02-20 | Initiated | ROTH Capital | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-05-19 | Initiated | Needham | Buy |
| Nov-26-19 | Initiated | BTIG Research | Buy |
| Jul-09-19 | Initiated | BofA/Merrill | Buy |
| Jun-03-19 | Initiated | Morgan Stanley | Overweight |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Nextcure Inc Stock (NXTC) Latest News
What margin trends mean for NextCure Inc. stock2025 Institutional Moves & Stock Timing and Entry Methods - ulpravda.ru
Will NextCure Inc. stock remain a Wall Street favorite2025 Technical Patterns & Weekly Breakout Stock Alerts - ulpravda.ru
Will NextCure Inc. stock maintain growth storyMarket Activity Report & Scalable Portfolio Growth Methods - ulpravda.ru
Will NextCure Inc. stock benefit from automation2025 Volume Leaders & AI Optimized Trade Strategies - ulpravda.ru
Will CO2 Energy Transition Corp. Equity Right stock outperform international peers2025 Price Targets & Low Drawdown Trading Strategies - ulpravda.ru
Why Intellinetics Inc. stock is trending among retail tradersLayoff News & Technical Buy Zone Confirmation - ulpravda.ru
How institutional buying supports NextCure Inc. stock2025 EndofYear Setup & Daily Profit Focused Screening - ulpravda.ru
Is NextCure Inc. stock resilient to inflationBull Run & High Yield Equity Trading Tips - ulpravda.ru
Risk Off: Why retail investors favor DRVN stock2025 AllTime Highs & Short-Term Trading Opportunity Alerts - moha.gov.vn
NextCure stock plunges to 52-week low, hits $0.69 - MSN
The Truth About NextCure Inc (NXTC): Hidden Biotech Underdog or Total Flop Stock? - AD HOC NEWS
Machinery Limited Builds Base for Possible ReboundFundamental Strength Indicators & Explosive Profit Growth - bollywoodhelpline.com
Options Data Show Bullish Bias in Foseco India LimitedValue Traps to Avoid & Explosive Profit Trading - bollywoodhelpline.com
Biocon Limited (BIOCON) vs yyyLong-Term Growth Stocks & Minimal Capital Growth Ideas - bollywoodhelpline.com
Jewellery Limited (LYPSAGEMS) Hits 52 Week HighDividend Stability Analysis & High Profit Investment Ideas - bollywoodhelpline.com
Short Interest in NextCure, Inc. (NASDAQ:NXTC) Expands By 29.6% - Defense World
Growth Review: Will NextCure Inc stock remain a Wall Street favoritePortfolio Value Summary & Fast Momentum Entry Tips - moha.gov.vn
Geopolitics Watch: Is NextCure Inc stock resilient to inflationEarnings Summary Report & Scalable Portfolio Growth Ideas - moha.gov.vn
Everest Kanto Cylinder Limited Stock Lags Behind Sector BenchmarksMarket Sentiment Indicators & Superior Trading Portfolio - Bollywood Helpline
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and NextCure (NASDAQ:NXTC) - Defense World
Is NextCure Inc. stock a buy on dips2025 Market WrapUp & Stock Market Timing Techniques - Улправда
NextCure Launches At-The-Market Stock Offering Program - The Globe and Mail
NextCure Enters ATM Offering Agreement - TradingView — Track All Markets
Is NextCure Inc. stock positioned well for digital economyQuarterly Trade Review & Long Hold Capital Preservation Plans - DonanımHaber
Aug Mood: Is NextCure Inc. stock a buy on dipsJuly 2025 Closing Moves & Weekly Market Pulse Updates - Улправда
Swing Trade: Is NextCure Inc. stock a buy on dips2025 Earnings Impact & Weekly Stock Breakout Alerts - Улправда
Death Cross: Can NextCure Inc. stock surprise with earnings upsideJuly 2025 Analyst Calls & Stock Portfolio Risk Management - Улправда
Can NextCure Inc. stock surprise with earnings upsideWeekly Trade Recap & Technical Pattern Based Signals - Улправда
NextCure (NASDAQ:NXTC) Upgraded to “Hold” at Wall Street Zen - Defense World
What sentiment indicators say about NextCure Inc. stockStock Surge & Risk Adjusted Buy/Sell Alerts - Newser
How analysts rate NextCure Inc. stock todayJuly 2025 Fed Impact & Fast Entry High Yield Stock Tips - Newser
What is the fair value of NextCure Inc. stock nowJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - Newser
Will NextCure Inc. stock deliver long term returnsWeekly Profit Report & High Return Trade Guides - Newser
NextCure files for offering of up to 2.52 million shares of common stock by selling stockholdersSEC filing - marketscreener.com
[S-3] NextCure, Inc. Shelf Registration Statement | NXTC SEC FilingForm S-3 - Stock Titan
Piper Sandler Keeps Their Buy Rating on NextCure (NXTC) - The Globe and Mail
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference - The Globe and Mail
NextCure (Nasdaq: NXTC) in fireside chat at Piper Sandler 37th Healthcare Conference - Stock Titan
NextCure Raises $21.5M in Private Placement - MSN
Will NextCure Inc. stock maintain momentum in 2025Trade Entry Summary & Reliable Trade Execution Plans - newser.com
Can NextCure Inc. stock sustain market leadershipQuarterly Portfolio Review & Expert Curated Trade Setup Alerts - newser.com
How currency fluctuations impact NextCure Inc. stockEarnings Overview Report & Precise Buy Zone Tips - newser.com
How NextCure Inc. stock reacts to inflationary pressuresJuly 2025 Drop Watch & Safe Entry Point Identification - newser.com
FY2025 EPS Estimates for NextCure Boosted by HC Wainwright - Defense World
NextCure Inc. recovery potential after sell offMarket Weekly Review & Fast Entry High Yield Stock Tips - newser.com
Nextcure Inc Stock (NXTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):